Introgen’s INGN 225 Molecular Cancer Vaccine Demonstrates Promising Results in Phase 2 Trial
January 29th, 2007
Approximately half of patients with advanced small cell lung cancer responded to Introgen Therapeutics, Inc.’s INGN 225 molecular cancer vaccine in combination with subsequent chemotherapy.